Source: Zero Hedge
Two weeks ago, the FDA begged a Texas judge to delay production on the first monthly batch of 55,000 pages of Covid-19 vaccine data submitted to the agency by Pfizer. Originally, the agency was set to produce just 500 pages-per-month.
Now, Pfizer – which just forecast $54 billion in Covid-related sales in 2022, appears to be anticipating some bad news, as evidenced by several redline changes in their Q4 earnings releases.
As Rubicon Capital’s Kelly Brown notes on Twitter, the changes center around disclosures of unfavorable safety data.
For example, in Q4 they added: “or further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection.”
More from Brown, who notes that Pfizer is now highlighting “concerns about clinical data integrity…”
Pfizer added new and peculiar items deep in its business risk disclosures re: clinical trial data, today in its Q4 earnings.— Kelly Brown (@rubiconcapital_) February 8, 2022
"…risks associated with…further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection;" pic.twitter.com/2GCjs0Bj3r
The company also notes that Covid-19 may “diminish in severity or prevalence, or disappear entirely.”
(3/3)— Kelly Brown (@rubiconcapital_) February 8, 2022
New risk disclosure regarding Covid-19 itself:
"…the possibility that COVID-19 will diminish in severity or prevalence, or disappear entirely;" pic.twitter.com/1nOK8fu8HQ